SQZ Biotechnologies logo

SQZ Biotechnologies(OTC) SQZ

Market CapN/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2020)-100%
5 Year-100%
1 Year-20%
1 Month+0%
N/A
SQZ Biotechnologies last closing stock price
MetricPriceDate
Last closeUSD 0.022026-10-14
SQZ Biotechnologies stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0%USD 0.022026-10-06
1 month+0%USD 0.022026-09-14
3 month+0%USD 0.022026-07-15
Year to date+0%USD 0.022025-12-31
1 year-20%USD 0.032025-10-14
3 year-60.07%USD 0.062023-10-13
5 year-99.98%USD 121.802021-10-15
Since inception-99.82%USD 13.252020-10-30

SQZ Biotechnologies Financials at a Glance

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$12.20M

Net Income (TTM)

-$3.40M

EPS (TTM)

N/A

P/E Ratio

N/A

Dividend

N/A

Beta (Volatility)

N/A

Price

N/A

Volume

N/A

Open

N/A

Previous Close

N/A

Daily Range

N/A

52-Week Range

N/A

Estimated Earnings Date

Aug 2, 2023

SQZ News

Laboratory

Why SQZ Biotechnologies Sank on Friday

Eric VolkmanFeb 12, 2021

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About SQZ Biotechnologies

SQZ Biotechnologies Company is a clinical-stage biotechnology firm focused on developing innovative cell therapies for cancer, infectious diseases, and other serious conditions. Headquartered in Watertown, Massachusetts, the company is advancing its lead product candidate, SQZ-PBMC-HPV, through clinical trials to address various solid tumors.

Products and Services
  • Lead product candidate SQZ-PBMC-HPV for HPV16+ advanced solid tumors
  • Development of SQZ-AAC-HPV and SQZ-eAPC-HPV in clinical trials
  • Additional platforms include SQZ Activating Antigen Carriers and SQZ Tolerizing Antigen Carriers
Growth Outlook
  • Strong pipeline with multiple candidates in Phase I clinical trials
  • Potential market expansion as therapies target various cancer types
  • Focus on innovative cell therapy technology may attract strategic partnerships
Financial Highlights
  • Recent quarterly revenue of $0, reflecting ongoing development phase
  • Cash and cash equivalents of $10.2 million as of September 30, 2023
  • Current ratio of 3.12 indicates strong liquidity position
SQZ Biotechnologies Company is positioned in the biotechnology sector, focusing on cutting-edge therapies that address significant medical needs. The company’s lead candidate, SQZ-PBMC-HPV, is currently in a Phase I clinical trial, showcasing its commitment to advancing innovative treatments. The development of additional product candidates further enhances its potential for growth in the competitive biotechnology landscape. Financially, the company is navigating its clinical-stage operations with a focus on research and development, which is reflected in its recent quarterly financials. Despite reporting no revenue in the latest quarter, the company maintains a solid cash position, allowing it to continue its research efforts. The current ratio indicates a strong liquidity position, which is crucial for sustaining operations during the development phase. Overall, SQZ Biotechnologies Company presents an intriguing opportunity for investors interested in the biotechnology sector, particularly those focused on innovative therapies for serious health conditions.
AI Generated • Sep 29, 2026

Industry

Biotechnology

Sector

Health Care

Employees

53

CEO

Howard Bernstein, MD, PhD

Website

www.sqzbiotech.com

Headquarters

Watertown, MA 02472, US

SQZ Financials

Key Financial Metrics (TTM)

Gross Margin

46.57%

Operating Margin

-383.68%

Net Income Margin

-377.88%

Return on Equity

-87.75%

Return on Capital

-95.35%

Return on Assets

-74.14%

Earnings Yield

N/A

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

N/A

Volume

N/A

Avg. Volume

N/A

Financials (TTM)

Gross Profit

$12.20M

Operating Income

-$73.19M

EBITDA

-$64.20M

Operating Cash Flow

-$55.92M

Capital Expenditure

-$213.00K

Free Cash Flow

-$56.13M

Cash & ST Invst.

$10.19M

Total Debt

$21.47M

SQZ Biotechnologies Performance Analysis

SQZ Biotechnologies annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20212021-12-31USD 27,098,000N/A
20222022-12-31USD 21,478,000-20.7%
SQZ Biotechnologies sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42022-12-31284.0%
Q12023-03-31-100.0%
Q22023-06-30N/A
Q32023-09-30-100.0%
SQZ Biotechnologies annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20212021-12-31USD -2.49N/A
20222022-12-31USD -2.7610.6%
SQZ Biotechnologies sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q42022-12-31239.5%
Q12023-03-31-154.7%
Q22023-06-301.7%
Q32023-09-30100.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q3 2023YOY CHG

Revenue

$0.00

-100.0%

Gross Profit

$0.00

-100.0%

Gross Margin

0.00%

N/A

Market Cap

N/AMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

N/A

N/A

Employees

53

N/A

Net Income

$0.00

+100.0%

EBITDA

-$23.80M

-17.6%

Quarterly Fundamentals

Name
Q3 2023YOY CHG

Total Cash

$10.19M

-87.9%

Total Debt

$21.47M

-65.6%

Accounts Receivable

$0.00

N/A

Inventory

$0.00

N/A

Long Term Debt

$19.08M

-63.2%

Short Term Debt

$2.40M

-77.4%

Return on Assets

-74.14%

N/A

Return on Invested Capital

-94.54%

N/A

Free Cash Flow

$3.88M

+117.7%

Operating Cash Flow

$3.88M

+117.8%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
HURATuHURA Biosciences, Inc.
$1.76-2.76%
CYADCelyad Oncology S.A.
$0.47-12.96%
KRROKorro Bio, Inc.
$8.88+0.79%
AMTIApplied Molecular Transport Inc.
$0.26-3.13%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$221.30-3.16%
BACBank of America
$51.39-4.76%
CRWVCoreWeave
$65.78-15.46%
SOXLDirexion Shares ETF Trust - Direxion Daily Semiconductor Bull 3x ETF
$110.54-13.35%

Questions About SQZ

What is the current price of SQZ Biotechnologies?

SQZ Biotechnologies is trading at N/A per share.

What is the 52-week range for SQZ Biotechnologies?

Over the past 52 weeks, SQZ Biotechnologies has traded between N/A and N/A.

How much debt does SQZ Biotechnologies have?

As of the most recent reporting period, SQZ Biotechnologies reported total debt of $27.47M.

How much cash does SQZ Biotechnologies have on hand?

SQZ Biotechnologies reported $63.71M in cash and cash equivalents in its most recent financial results.

What is SQZ Biotechnologies’s dividend yield?

SQZ Biotechnologies does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services